CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Drugs.com New Drug Applications
Original article

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission

NDA FilingAnaphylmPositive
AI Analysis

Summary

Aquestive Therapeutics announced on Oct. 15, 2026 that the FDA has accepted its NDA resubmission for Anaphylm.

Outcome Details

FDA accepted the NDA resubmission for Anaphylm

Importance:7/10
Sentiment:
0.50
FDANDA resubmissionregulatory
Related Companies

Read the original article

Published by Drugs.com New Drug Applications on October 15, 2026 10:10 PM

Read Original